Tumor Biomarker Test Market Overview
The Tumor Biomarker Test Market is expanding as the global cancer burden rises and demand for early diagnosis, personalized medicine, and targeted therapies increases. Technological advancements in genomics, proteomics, next-generation sequencing, artificial intelligence, and liquid biopsy are supporting the development of more precise and efficient tumor biomarker testing solutions.
According to the WiseGuyReports market report published in June 2026, the global Tumor Biomarker Test Market was valued at USD 5.4 Billion in 2024 and USD 5.7 Billion in 2025 and is projected to reach USD 10.2 Billion by 2035, registering a CAGR of 6.0% during 2026–2035. North America held the largest market position, valued at USD 2.3 Billion in 2024 and projected to reach USD 4.0 Billion by 2035. Genetic Biomarkers represented the leading test type, valued at USD 2.0 Billion in 2024 and projected to reach USD 3.5 Billion by 2035.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.wiseguyreports.com/sample-request?id=596248
Key players driving innovation and competitiveness in the Tumor Biomarker Test Market include:
Qiagen
Myriad Genetics
Bio-Rad Laboratories
Roche
Laboratory Corporation of America
Medtronic
Thermo Fisher Scientific
Abbott
Eurofins Scientific
Hologic
Illumina
Agilent Technologies
The market is being shaped by increasing cancer prevalence, growing demand for personalized medicine, advances in genomic technologies, and increasing investment in oncology research. Tumor biomarker tests are becoming increasingly important for cancer diagnosis, prognosis, treatment selection, and monitoring treatment response. Artificial intelligence and machine learning are also supporting biomarker discovery and improving diagnostic workflows.
The Tumor Biomarker Test Market can be segmented by Test Type into Protein Biomarkers, Genetic Biomarkers, Epigenetic Biomarkers, and Metabolic Biomarkers. By Application, it includes Cancer Diagnosis, Cancer Prognosis, Treatment Selection, and Monitoring Treatment Response. By Technology, it covers Immunohistochemistry, Polymerase Chain Reaction, Next-Generation Sequencing, and In Situ Hybridization. By End Use, it includes Hospitals, Diagnostic Laboratories, Research Institutions, and Home Care Settings. Regionally, the market covers North America, Europe, South America, Asia Pacific, and the Middle East and Africa.
The growing need for precise cancer diagnostics and personalized treatment is creating opportunities for diagnostic companies, pharmaceutical manufacturers, biotechnology firms, research institutions, and healthcare providers. Liquid biopsy, next-generation sequencing, AI-assisted biomarker analysis, targeted therapy development, and expanded testing capabilities can support market differentiation and future growth.
Recent Developments and Market Trends:
Genetic Biomarkers remain the leading test type, valued at USD 2.0 Billion in 2024 and projected to reach USD 3.5 Billion by 2035.
Liquid biopsy is gaining traction because it provides a less invasive approach to tumor biomarker testing and can support faster cancer assessment.
Next-generation sequencing is enabling comprehensive genomic profiling and identification of mutations that can guide targeted treatment decisions.
Artificial intelligence and machine learning are increasingly being integrated into biomarker discovery and analysis to improve accuracy and efficiency.
In March 2025, Roche announced a strategic collaboration with Foundation Medicine to advance integrated tissue and liquid biopsy tumor biomarker profiling across multiple cancer types.
In June 2024, Illumina announced a comprehensive oncology biomarker panel integrating DNA and RNA targets to support targeted therapy decisions.
In January 2025, Myriad Genetics announced a major contract to deploy Oncotype DX biomarker testing across a national health system.
North America remains the leading regional market, supported by advanced healthcare infrastructure, high healthcare expenditure, and significant investment in precision medicine and cancer research.
Asia Pacific is expected to witness significant growth as cancer prevalence, healthcare investments, diagnostic capabilities, and awareness of personalized medicine increase.
Reasons to Buy the Report:
Provides comprehensive insights into the Tumor Biomarker Test Market dynamics, trends, opportunities, and growth potential.
Helps identify opportunities across protein, genetic, epigenetic, and metabolic biomarkers.
Offers detailed segmentation analysis across test type, application, technology, end use, and geographic markets.
Includes competitive intelligence covering leading diagnostic, biotechnology, pharmaceutical, and healthcare companies.
Supports informed decisions using market forecasts, cancer prevalence trends, precision medicine adoption, genomic technology advancements, liquid biopsy development, and regional opportunities.
Future Outlook:
The future of the Tumor Biomarker Test Market will be shaped by rising cancer prevalence, increasing demand for personalized medicine, advances in genomic technologies, AI-assisted diagnostics, and growing research funding. Genetic Biomarkers should remain the leading test type, with its market value projected to increase from USD 2.0 Billion in 2024 to USD 3.5 Billion by 2035. North America is expected to retain its leadership position, with the regional market projected to grow from USD 2.3 Billion in 2024 to USD 4.0 Billion by 2035. Europe is expected to reach USD 2.9 Billion by 2035, while South America is projected to reach USD 0.7 Billion. Liquid biopsy and next-generation sequencing are positioned for continued expansion as cancer care increasingly moves toward earlier detection and personalized treatment. The global Tumor Biomarker Test Market is projected to reach USD 10.2 Billion by 2035 at a CAGR of 6.0%.
➤➤Explore Our Latest Related Reports:
